Karyopharm Announces Financing and Positive SENTRY Trial Results

Karyopharm Therapeutics ( (KPTI) ) has provided an update.

On March 24, 2026, Karyopharm announced a $30 million private placement with RA Capital Management, issuing common stock, pre-funded warrants and additional common stock warrants, with potential extra proceeds of about $44 million upon full warrant exercise. The financing, alongside approximately $9.6 million raised via its at-the-market program earlier in March, is intended to fund general corporate purposes and clinical trials and will satisfy a key capital-raise condition to activate previously agreed amendments and forbearance on its credit facilities and convertible notes.

The same day, the company reported topline data from its pivotal Phase 3 SENTRY trial in frontline myelofibrosis, where selinexor plus ruxolitinib met one co-primary endpoint with a near-doubling of spleen volume responses versus ruxolitinib alone but did not improve symptoms over control. Investigators observed a promising overall survival signal and evidence of potential disease modification, with a manageable safety profile, positioning Karyopharm to discuss a supplemental U.S. filing and potentially strengthen selinexor’s role in myelofibrosis while it awaits additional Phase 2 and Phase 3 readouts in 2026.

Also in March 2026, Karyopharm agreed to voluntarily withdraw the accelerated approval of XPOVIO’s diffuse large B-cell lymphoma indication at the FDA’s request, after concluding the required confirmatory trial was no longer feasible in an evolving treatment landscape. The move, which affects an indication that generates only immaterial revenue and leaves other XPOVIO approvals intact, allows the company to halt development spending in DLBCL and reallocate resources toward more commercially and clinically viable programs.

The most recent analyst rating on (KPTI) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.

Spark’s Take on KPTI Stock

According to Spark, TipRanks’ AI Analyst, KPTI is a Neutral.

Overall score reflects weak financial performance (persistent losses, negative equity, ongoing cash burn) as the main constraint. This is partially offset by strong technical momentum and a mixed earnings outlook with cost reductions and meaningful upcoming clinical catalysts, but a negative P/E and no dividend limit valuation support.

To see Spark’s full report on KPTI stock, click here.

More about Karyopharm Therapeutics

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies, including the XPO1 inhibitor selinexor. The company targets hematologic malignancies and solid tumors, with a market focus on advancing combination regimens in indications such as myelofibrosis, endometrial cancer and other difficult-to-treat cancers.

Average Trading Volume: 612,095

Technical Sentiment Signal: Sell

Current Market Cap: $122.2M

For detailed information about KPTI stock, go to TipRanks’ Stock Analysis page.